Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2506PDF: 1936HTML: 1093 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3568PDF: 1653HTML: 4094 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5212PDF: 3020HTML: 2381 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3514PDF: 1030HTML: 4974 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2721PDF: 922HTML: 9076Efremov 1: 278Efremov 2: 247 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3112PDF: 1105HTML: 5674 -
TYROSINE KINASE INHIBITORS AND INTERFERON
3055PDF: 1526HTML: 3106Cover Letter: 272 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1935PDF: 1274HTML: 366 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4232PDF: 1649HTML: 9331Untitled: 344Untitled: 232Untitled: 218Untitled: 229Untitled: 232Untitled: 393 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3373PDF: 1441HTML: 4168 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1769HTML: 716PDF: 933 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2415PDF: 960HTML: 2030Fig 1 Rossi: 250 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3080PDF: 1364HTML: 2853Figure 1: 224 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3900PDF: 1803HTML: 2783 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
2039PDF: 911HTML: 10375Figures 1,2,3: 317 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1648PDF: 1036HTML: 271 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2447PDF: 1136HTML: 2038Characteristic of study group: 263 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1643PDF: 1352HTML: 542 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277947PDF: 1913HTML: 3916 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4806PDF: 3959HTML: 383 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2518PDF: 1407HTML: 17236Bassan Fig.1: 187Bassan Fig.2: 292Bassan Fig.4: 175Fig.3: 305 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4497PDF: 2057HTML: 5570Table 1: 300 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1931PDF: 583HTML: 369 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2046PDF: 1264HTML: 352 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
4017PDF: 1783HTML: 11969Figures Haase: 304 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1819PDF: 1178HTML: 200 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2513PDF: 668HTML: 389 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1283PDF: 675Suppl. Files: 154HTML: 552 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1847PDF: 872HTML: 934jdoe, table 2 infections CML .doc: 255jdoe, table 1 infections CML .doc: 233 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2336PDF: 918HTML: 271







